Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. (9th July 2018)

• Record Type: Journal Article
• Authors: Royle, Kara‐Louise; Gregory, Walter M.; Cairns, David A.; Bell, Sue E.; Cook, Gordon; Owen, Roger G.; Drayson, Mark T.; Davies, Faith E.; Jackson, Graham H.; Morgan, Gareth J.; Child, J. Anthony
• Is Part Of: British journal of haematology. Volume 182:Number 6(2018)
• Page Start: 816
• Page End: 829
• Publication Date: 2018-07-09
• Subjects: multiple myeloma -- quality of life -- EORTC QLQ‐C30 -- EORTC MY‐24 -- immunomodulatory agent; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15459
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to sodium clodronate or zoledronic acid and induction treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) or cyclophosphamide, thalidomide and dexamethasone (CTD) followed by autologous stem cell transplant (ASCT) in the intensive pathway; attenuated CTD or melphalan and prednisolone (MP) in the non‐intensive pathway. Subsequent randomisation allocated patients to either thalidomide or observation. The European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QoL) questionnaires, QLQ‐C30 and QLQ‐MY24, were administered at baseline, 3, 6 and 12 months and annually thereafter, enabling the effect of sequential treatment on patient‐reported health‐related QoL (HR‐QoL) to be investigated. The protocol specified four subscales of interest: Pain, Fatigue, Global Health Status/Quality of Life and Physical Functioning at 3, 6 and 12 months that were compared using linear models. The intensive pathway showed significant differences in favour of CTD for Fatigue at 3 months and Physical Functioning at 12 months. The non‐intensive pathway and maintenance phase reported significant differences at 3 months; Pain (improved with attenuated CTD) and Global Health status/Quality of Life (improved with observation). The improved outcomes in MRC Myeloma IX were accompanied by some beneficial and few detrimental effects on HR‐QoL.